FOLH1 and prostate cancer: Studies have included 203/212Pb-labeled PSMA and gastrin-releasing peptide receptor-targeting agents for imaging and radiotherapy of prostate-cancer-bearing mice [60,61,74,75], and 203/212Pb-labeled anti-melanin antibodies and melanocortin subtype 1 receptor targeting ligands for imaging and therapy of melanoma-bearing mice [59,72,73,76,77,78,79].